EGFR and non-small cell lung carcinoma: Erlotinib is one of the earliest EGFR-TKIs, and it has been shown to be effective in NSCLC patients with or without EGFR-activating mutations, but it is even more potent in patient with EGFR activating mutations (Tsao et al., 2005; Qi et al., 2012; Kobayashi and Hagiwara, 2013).